3171 results for «414»

Filter By

3171 results

Protect the brain for TAVI - True potential of SENTINEL Cerebral Protection System

14 Feb 2026 – From PCR Tokyo Valves 2026

This session highlights the critical role of cerebral protection during TAVI procedures by focusing on the SENTINEL Cerebral Protection System. It reviews trends in the United States and Japan, presents clinical outcomes one year post-introduction in Japan, and examines key clinical trials through a meta-analysis comparing...

Protect the brain for TAVI - True potential of SENTINEL Cerebral Protection System

Mastering techniques from basic to complex - Tips and tricks for advanced mitral TEER: anatomy and imaging

13 Feb 2026 – From PCR Tokyo Valves 2026

Advance your expertise in mitral TEER by gaining anatomical insights, understanding device interaction with native valve structures, and learning to prevent and manage procedural complications through case-based imaging and live assessments.

Mastering techniques from basic to complex - Tips and tricks for advanced mitral TEER: anatomy and imaging

Mastering techniques from basic to complex - Tricuspid TEER fundamentals

13 Feb 2026 – From PCR Tokyo Valves 2026

Gain foundational knowledge in tricuspid TEER by understanding anatomical criteria for patient suitability, key procedural steps, and device techniques, enhanced by simulation-based procedural training.

Mastering techniques from basic to complex - Tricuspid TEER fundamentals

Getting ready for tricuspid TEER: key steps in building a successful programme

14 Feb 2026 – From PCR Tokyo Valves 2026

Prepare to establish a successful tricuspid TEER programme by understanding essential components such as systematic echocardiographic and clinical assessments for patient selection, procedural fundamentals, and programme development supported by clinical evidence.

Getting ready for tricuspid TEER: key steps in building a successful programme

Patient selection for tricuspid TEER in 2026

14 Feb 2026 – From PCR Tokyo Valves 2026

This session focuses on optimizing patient selection for tricuspid transcatheter edge-to-edge repair (TEER) in 2026. It integrates anatomical, haemodynamic, and clinical criteria to identify ideal candidates, explores evolving treatment boundaries between TEER, transcatheter tricuspid valve replacement (TTVR), and medical management, and applies evidence from key trials...

Patient selection for tricuspid TEER in 2026

Procedural optimisation for enhanced acute and long-term outcomes

14 Feb 2026 – From PCR Tokyo Valves 2026

This session emphasizes procedural optimization in TAVI to enhance both acute and long-term outcomes. It highlights critical factors such as valve sizing, expansion, implantation depth, and commissural alignment. Practical techniques for pre- and post-dilatation alongside commissural alignment are demonstrated through real cath lab cases, underscoring their...

Procedural optimisation for enhanced acute and long-term outcomes

Team approach to structural heart disease: how to handle unexpected situations

14 Feb 2026 – From PCR Tokyo Valves 2026

This session highlights the multidisciplinary team approach to managing structural heart disease, focusing on responses to unexpected intraoperative and postoperative situations. It features real-world experiences from a TAVI radiologic technologist, clinical engineer, TEER sonographer, and TEER nurse, emphasizing their respective roles in addressing intraoperative events, sudden...

Team approach to structural heart disease: how to handle unexpected situations

Four-Year Outcomes from the EVOLUT Low Risk Trial

26 Oct 2023

Dejan Milasinovic provides his take on the EVOLUT Low Risk trial, presented by Michael I. Reardon at TCT Congress 2023. 4-year results reveal a continuing trend towards lower combined rates of all-cause mortality and disabling stroke with TAVI compared with surgical aortic valve replacement (SAVR)

Dejan Milasinovic

Author

Dejan Milasinovic
Four-Year Outcomes from the EVOLUT Low Risk Trial

5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)

01 Apr 2025

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.

Yohei Ohno

Author

Yohei Ohno
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)

Cardiac biomarkers in patients with asymptomatic severe aortic stenosis: primary biomarker analysis from the EARLY TAVR Trial

01 Apr 2025

Elad Asher provides his take on the primary biomarker analysis from the EARLY TAVR Trial presented by Brian R. Lindman at ACC.25 in Chicago.

Elad Asher

Author

Elad Asher
Cardiac biomarkers in patients with asymptomatic severe aortic stenosis: Primary biomarker analysis from the EARLY TAVR Trial

Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial

05 Mar 2023

Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.

Luigi Biasco

Author

Luigi Biasco
Transcatheter versus surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut low risk Trial
Didn’t find what you were looking for?